{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:57:15Z","timestamp":1762376235459},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T00:00:00Z","timestamp":1493337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T00:00:00Z","timestamp":1493337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Niemann-Pick Type C disease (NPC) is a rare metabolic disorder characterized by disruption of normal cholesterol trafficking within the cells of the body. There are no FDA approved treatments available for NPC patients. Recently, the cycloheptaglucoside 2-hydroxypropyl-\u03b2-cyclodextrin (HP-\u03b2-CD) has shown efficacy as a potential NPC therapeutic by extending lifetime in NPC mice, delaying neurodegeneration, and decreasing visceral and neurological cholesterol burden. Although promising, systemic HP-\u03b2-CD treatment is limited by a pharmacokinetic profile characterized by rapid loss through renal filtration. To address these shortcomings, we sought to design a family of HP-\u03b2-CD pro-drug delivery vehicles, known as polyrotaxanes (PR), capable of increasing the efficacy of a given injected dose by improving both pharmacokinetic profile and bioavailability of the HP-\u03b2-CD agent. PR can effectively diminish the cholesterol pool within the liver, spleen, and kidney at molar concentrations 10-to-100-fold lower than monomeric HP-\u03b2-CD. In addition to this proof-of-concept, use of PR scaffolds with differing physiochemical properties reveal structure-activity relationships in which PR characteristics, including hydrophobicity, threading efficiency and surface charge, were found to both decisively and subtly effect therapeutic efficacy. PR scaffolds exhibit absorption, pharmacokinetics, and biodistribution patterns that are significantly altered from monomeric HP-\u03b2-CD. In all, PR scaffolds hold great promise as potential treatments for visceral disease in NPC patients.<\/jats:p>","DOI":"10.1038\/srep46737","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T09:11:01Z","timestamp":1493370661000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Pluronic based \u03b2-cyclodextrin polyrotaxanes for treatment of Niemann-Pick Type C disease"],"prefix":"10.1038","volume":"7","author":[{"given":"Christopher J.","family":"Collins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley P.","family":"Loren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Suhail","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yawo","family":"Mondjinou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph L.","family":"Skulsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheyenne R.","family":"Chaplain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasturi","family":"Haldar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,28]]},"reference":[{"key":"BFsrep46737_CR1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1034\/j.1399-0004.2003.00147.x","volume":"64","author":"MT Vanier","year":"2003","unstructured":"Vanier, M. T. & Millat, G. Niemann-Pick disease type C. Clin. Genet. 64, 269\u2013281 (2003).","journal-title":"Clin. Genet"},{"key":"BFsrep46737_CR2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-5-16","volume":"5","author":"MT Vanier","year":"2010","unstructured":"Vanier, M. T. Niemann-Pick disease type C. Orphanet J. Rare Dis. 5, 16 (2010).","journal-title":"Orphanet J. Rare Dis."},{"key":"BFsrep46737_CR3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/clp.12.31","volume":"7","author":"B Liu","year":"2012","unstructured":"Liu, B. Therapeutic potential of cyclodextrins in the treatment of Niemann\u2013Pick type C disease. Clin. Lipidol. 7, 289\u2013301 (2012).","journal-title":"Clin. Lipidol"},{"key":"BFsrep46737_CR4","doi-asserted-by":"crossref","first-page":"12391","DOI":"10.1073\/pnas.221181998","volume":"98","author":"Y Sugimoto","year":"2001","unstructured":"Sugimoto, Y. et al. Accumulation of cholera toxin and GM1 ganglioside in the early endosome of Niemann-Pick C1-deficient cells. Proc. Natl. Acad. Sci. 98, 12391\u201312396 (2001).","journal-title":"Proc. Natl. Acad. Sci"},{"key":"BFsrep46737_CR5","doi-asserted-by":"crossref","first-page":"9627","DOI":"10.1074\/jbc.274.14.9627","volume":"274","author":"EB Neufeld","year":"1999","unstructured":"Neufeld, E. B. et al. The Niemann-Pick C1 protein resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo. J. Biol. Chem. 274, 9627\u20139635 (1999).","journal-title":"J. Biol. Chem."},{"key":"BFsrep46737_CR6","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1074\/jbc.M005393200","volume":"276","author":"M Zhang","year":"2001","unstructured":"Zhang, M. et al. Sterol-modulated glycolipid sorting occurs in Niemann-Pick C1 late endosomes. J. Biol. Chem. 276, 3417\u20133425 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFsrep46737_CR7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0958-1669(99)00031-2","volume":"10","author":"JJ Repa","year":"1999","unstructured":"Repa, J. J. & Mangelsdorf, D. J. Nuclear receptor regulation of cholesterol and bile acid metabolism. Curr. Opin. Biotechnol. 10, 557\u2013563 (1999).","journal-title":"Curr. Opin. Biotechnol."},{"key":"BFsrep46737_CR8","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ymgme.2009.06.009","volume":"98","author":"JE Wraith","year":"2009","unstructured":"Wraith, J. E. et al. Natural history of Niemann-Pick disease type C in a multicentre observational retrospective cohort study. Mol. Genet. Metab. 98, 250\u2013254 (2009).","journal-title":"Mol. Genet. Metab."},{"key":"BFsrep46737_CR9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40265-013-0164-6","volume":"74","author":"KA Lyseng-Williamson","year":"2014","unstructured":"Lyseng-Williamson, K. A. Miglustat: a review of its use in Niemann-Pick disease type C. Drugs 74, 61\u201374 (2014).","journal-title":"Drugs"},{"key":"BFsrep46737_CR10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ymgme.2009.11.007","volume":"99","author":"M Pineda","year":"2010","unstructured":"Pineda, M. et al. Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series. Mol. Genet. Metab. 99, 358\u2013366 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"BFsrep46737_CR11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ymgme.2009.12.006","volume":"99","author":"JE Wraith","year":"2010","unstructured":"Wraith, J. E. et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol. Genet. Metab. 99, 351\u2013357 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"BFsrep46737_CR12","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1476-5381.2010.01188.x","volume":"162","author":"C Tiffon","year":"2011","unstructured":"Tiffon, C. et al. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br. J. Pharmacol. 162, 1590\u20131602 (2011).","journal-title":"Br. J. Pharmacol"},{"key":"BFsrep46737_CR13","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s13311-013-0217-2","volume":"10","author":"P Helquist","year":"2013","unstructured":"Helquist, P., Maxfield, F. R., Wiech, N. L. & Wiest, O. Treatment of Niemann-Pick type C disease by histone deacetylase inhibitors. Neurotherapeutics. 10, 688\u2013697 (2013).","journal-title":"Neurotherapeutics."},{"key":"BFsrep46737_CR14","first-page":"326ra323","volume":"8","author":"MS Alam","year":"2016","unstructured":"Alam, M. S., Getz, M. & Haldar, K. Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model. Sci. Transl. Med. 8, 326ra323 (2016).","journal-title":"Sci. Transl. Med."},{"key":"BFsrep46737_CR15","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1073\/pnas.0810895106","volume":"106","author":"B Liu","year":"2009","unstructured":"Liu, B. et al. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1\u2212\/\u2212 mouse. Proc. Natl. Acad. Sci. 106, 2377\u20132382 (2009).","journal-title":"Proc. Natl. Acad. Sci"},{"key":"BFsrep46737_CR16","doi-asserted-by":"crossref","first-page":"e6951","DOI":"10.1371\/journal.pone.0006951","volume":"4","author":"CD Davidson","year":"2009","unstructured":"Davidson, C. D. et al. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PloS One. 4, e6951 (2009).","journal-title":"PloS One."},{"key":"BFsrep46737_CR17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1203\/PDR.0b013e3181ee4dd2","volume":"68","author":"CM Ramirez","year":"2010","unstructured":"Ramirez, C. M. et al. Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life. Pediatr. Res. 68, 309\u2013315 (2010).","journal-title":"Pediatr. Res."},{"key":"BFsrep46737_CR18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/acn3.306","volume":"3","author":"CD Davidson","year":"2016","unstructured":"Davidson, C. D. et al. Efficacy and ototoxicity of different cyclodextrins in Niemann-Pick C disease. Ann. Clin. Trans. Neurol. 3, 366\u2013380 (2016).","journal-title":"Ann. Clin. Trans. Neurol"},{"key":"BFsrep46737_CR19","doi-asserted-by":"crossref","first-page":"9404","DOI":"10.1523\/JNEUROSCI.1317-11.2011","volume":"31","author":"A Aqul","year":"2011","unstructured":"Aqul, A. et al. Unesterified cholesterol accumulation in late endosomes\/lysosomes causes neurodegeneration and is prevented by driving cholesterol export from this compartment. J. Neurosci. 31, 9404\u20139413 (2011).","journal-title":"J. Neurosci."},{"key":"BFsrep46737_CR20","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/S0022-2275(20)34940-3","volume":"38","author":"A Christian","year":"1997","unstructured":"Christian, A., Haynes, M., Phillips, M. & Rothblat, G. Use of cyclodextrins for manipulating cellular cholesterol content. J. Lipid Res. 38, 2264\u20132272 (1997).","journal-title":"J. Lipid Res."},{"key":"BFsrep46737_CR21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1203\/PDR.0b013e3181df4623","volume":"68","author":"S Ward","year":"2010","unstructured":"Ward, S., O\u2019Donnell, P., Fernandez, S. & Vite, C. H. 2-Hydroxypropyl-\u03b2-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick Type C disease. Pediatr. Res. 68, 52\u201356 (2010).","journal-title":"Pediatr. Res."},{"key":"BFsrep46737_CR22","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1023\/A:1015929720063","volume":"7","author":"HW Frijlink","year":"1990","unstructured":"Frijlink, H. W. et al. The pharmacokinetics of \u03b2-cyclodextrin and hydroxypropyl-\u03b2-cyclodextrin in the rat. Pharm. Res. 7, 1248\u20131252 (1990).","journal-title":"Pharm. Res"},{"key":"BFsrep46737_CR23","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1194\/jlr.M000257","volume":"51","author":"B Liu","year":"2010","unstructured":"Liu, B. et al. Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid. J. Lipid Res. 51, 933\u2013944 (2010).","journal-title":"J. Lipid Res."},{"key":"BFsrep46737_CR24","doi-asserted-by":"crossref","first-page":"23831","DOI":"10.1021\/acsami.5b01016","volume":"7","author":"YA Mondjinou","year":"2015","unstructured":"Mondjinou, Y. A . et al. Impact of mixed \u03b2-cyclodextrin ratios on Pluronic rotaxanation efficiency and product solubility. ACS Appl. Mater. Interfaces. 7, 23831\u201323836 (2015).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"BFsrep46737_CR25","doi-asserted-by":"crossref","first-page":"22272","DOI":"10.1021\/acsami.5b05393","volume":"7","author":"Z Zhou","year":"2015","unstructured":"Zhou, Z . et al. Gd3+-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic-2-hydroxypropyl-\u03b2-cyclodextrin\/Pluronic polyrotaxane as a long circulating high relaxivity MRI contrast agent. ACS Appl. Mater. Interfaces. 7, 22272\u201322276 (2015).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"BFsrep46737_CR26","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1021\/acs.biomac.6b00508","volume":"17","author":"CJ Collins","year":"2016","unstructured":"Collins, C. J. et al. Influence of molecular structure on the in vivo performance of flexible rod polyrotaxanes. Biomacromolecules. 17, 2777\u20132786 (2016).","journal-title":"Biomacromolecules."},{"key":"BFsrep46737_CR27","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1021\/bi3010889","volume":"52","author":"CJ Collins","year":"2013","unstructured":"Collins, C. J. et al. Synthesis, characterization, and evaluation of pluronic-based \u03b2-cyclodextrin polyrotaxanes for mobilization of accumulated cholesterol from Niemann-Pick Type C fibroblasts. Biochemistry. 52, 3242\u20133253 (2013).","journal-title":"Biochemistry."},{"key":"BFsrep46737_CR28","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1021\/bm400922a","volume":"14","author":"YA Mondjinou","year":"2013","unstructured":"Mondjinou, Y. A. et al. Synthesis of 2-hydroxypropyl-\u03b2-cyclodextrin\/Pluronic-based polyrotaxanes via heterogeneous reaction as potential Niemann-Pick Type C therapeutics. Biomacromolecules. 14, 4189\u20134197 (2013).","journal-title":"Biomacromolecules."},{"key":"BFsrep46737_CR29","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1038\/srep04356","volume":"4","author":"A Tamura","year":"2014","unstructured":"Tamura, A. & Yui, N. Lysosomal-specific cholesterol reduction by biocleavable polyrotaxanes for ameliorating Niemann-Pick Type C Disease. Sci. Rep. 4, 4356 (2014).","journal-title":"Sci. Rep"},{"key":"BFsrep46737_CR30","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.taap.2009.11.002","volume":"242","author":"E Fr\u00f6hlich","year":"2010","unstructured":"Fr\u00f6hlich, E. et al. Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes. Toxicol. Appl. Pharmacol. 242, 326\u2013332 (2010).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"BFsrep46737_CR31","doi-asserted-by":"crossref","first-page":"e0152007","DOI":"10.1371\/journal.pone.0152007","volume":"11","author":"E-R Nicoli","year":"2016","unstructured":"Nicoli, E.-R. et al. Defective Cytochrome P450-catalysed drug metabolism in Niemann-Pick Type C disease. PLoS One 11, e0152007 (2016).","journal-title":"PLoS One"},{"key":"BFsrep46737_CR32","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1194\/jlr.D800017-JLR200","volume":"49","author":"A Honda","year":"2008","unstructured":"Honda, A. et al. Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS\/MS. J. Lipid Res. 49, 2063\u20132073 (2008).","journal-title":"J. Lipid Res."},{"key":"BFsrep46737_CR33","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1248\/bpb.b14-00726","volume":"38","author":"Y Tanaka","year":"2015","unstructured":"Tanaka, Y. et al. Efficacy of 2-hydroxypropyl-\u03b2-cyclodextrin in Niemann\u2013Pick disease type C model mice and its pharmacokinetic analysis in a patient with the disease. Biol. Pharm. Bull. 38, 844\u2013851 (2015).","journal-title":"Biol. Pharm. Bull."},{"key":"BFsrep46737_CR34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1203\/PDR.0b013e3181ee4dd2","volume":"68","author":"CM Ramirez","year":"2010","unstructured":"Ramirez, C. M. et al. Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life. Pediatr. Res. 68, 309\u2013315 (2010).","journal-title":"Pediatr. Res."},{"key":"BFsrep46737_CR35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jconrel.2005.02.028","volume":"105","author":"L Harivardhan Reddy","year":"2005","unstructured":"Harivardhan Reddy, L., Sharma, R. K., Chuttani, K., Mishra, A. K. & Murthy, R. S. R. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton\u2019s lymphoma tumor bearing mice. J. Controlled Release 105, 185\u2013198 (2005).","journal-title":"J. Controlled Release"},{"key":"BFsrep46737_CR36","doi-asserted-by":"crossref","first-page":"e24374","DOI":"10.1371\/journal.pone.0024374","volume":"6","author":"RR Arvizo","year":"2011","unstructured":"Arvizo, R. R. et al. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One 6, e24374 (2011).","journal-title":"PLoS One"},{"key":"BFsrep46737_CR37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1349-7006.2010.01747.x","volume":"102","author":"T Kamei","year":"2011","unstructured":"Kamei, T. et al. Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules. Cancer Sci. 102, 200\u2013205 (2011).","journal-title":"Cancer Sci"},{"key":"BFsrep46737_CR38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/jbm.a.30654","volume":"77A","author":"DS Kohane","year":"2006","unstructured":"Kohane, D. S. et al. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J. Biomed. Mater. Res., Part. A 77A, 351\u2013361 (2006).","journal-title":"J. Biomed. Mater. Res., Part. A"},{"key":"BFsrep46737_CR39","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1021\/cr010046q","volume":"102","author":"SE Wolkenberg","year":"2002","unstructured":"Wolkenberg, S. E. & Boger, D. L. Mechanisms of in situ activation for DNA-targeting antitumor agents. Chem. Rev. 102, 2477\u20132495 (2002).","journal-title":"Chem. Rev."},{"key":"BFsrep46737_CR40","doi-asserted-by":"crossref","first-page":"31750","DOI":"10.1038\/srep31750","volume":"6","author":"A Brown","year":"2016","unstructured":"Brown, A. et al. PEG-lipid micelles enable cholesterol efflux in Niemann-Pick type C1 disease-based lysosomal storage disorder. Sci. Rep. 6, 31750 (2016).","journal-title":"Sci. Rep"},{"key":"BFsrep46737_CR41","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2174\/138920007782798207","volume":"8","author":"L Jia","year":"2007","unstructured":"Jia, L. & Liu, X. The conduct of drug metabolism studies considered good practice (II): In vitro experiments. Curr. Drug Metab. 8, 822\u2013829 (2007).","journal-title":"Curr. Drug Metab."},{"key":"BFsrep46737_CR42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0169-409X(00)00139-3","volume":"46","author":"U Bickel","year":"2001","unstructured":"Bickel, U., Yoshikawa, T. & Pardridge, W. M. Delivery of peptides and proteins through the blood\u2013brain barrier. Adv. Drug Deliv. Rev. 46, 247\u2013279 (2001).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"BFsrep46737_CR43","doi-asserted-by":"crossref","first-page":"9925","DOI":"10.1021\/nn501069c","volume":"8","author":"J Li","year":"2014","unstructured":"Li, J. et al. A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer. ACS Nano 8, 9925\u20139940 (2014).","journal-title":"ACS Nano"},{"key":"BFsrep46737_CR44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1126\/science.277.5323.232","volume":"277","author":"SK Loftus","year":"1997","unstructured":"Loftus, S. K. et al. Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science. 277, 232\u2013235 (1997).","journal-title":"Science."},{"key":"BFsrep46737_CR45","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1074\/jbc.M113.526392","volume":"289","author":"MS Alam","year":"2014","unstructured":"Alam, M. S. et al. Plasma signature of neurological disease in the monogenetic disorder Niemann-Pick type C. J. Biol. Chem. 289, 8051\u20138066 (2014).","journal-title":"J. Biol. Chem."},{"key":"BFsrep46737_CR46","first-page":"1488","volume":"35","author":"A Ray","year":"2010","unstructured":"Ray, A. & Dittel, B. N. Isolation of mouse peritoneal cavity cells. J. Vis. Exp. 35, 1488 (2010).","journal-title":"J. Vis. Exp"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep46737.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep46737","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/srep46737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/srep46737.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T22:52:53Z","timestamp":1671835973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep46737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,28]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,9,25]]}},"alternative-id":["BFsrep46737"],"URL":"https:\/\/doi.org\/10.1038\/srep46737","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,28]]},"assertion":[{"value":"16 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46737"}}